Prescriber Scope of Practice for ADHD in Texas

You spent years training to diagnose and treat ADHD. Now you’re staring at a regulatory maze that makes medical school look straightforward: DEA waivers that keep getting extended, state laws that contradict each other, and conflicting advice about whether you can even prescribe Adderall over video.

Here’s what you actually need to know in 2026.

The Federal Landscape: You Can Prescribe ADHD Meds via Telehealth (For Now)

Bottom line first: Through December 31, 2026, you can legally prescribe Schedule II stimulants like Adderall, Vyvanse, and Ritalin via telehealth without an in-person exam, anywhere in the U.S. The DEA and HHS extended COVID-era flexibilities for the fourth time in January 2026, explicitly covering ‘Schedule II to Schedule V drugs, like Adderall’ through year-end.

But the clock is ticking. The DEA is finalizing permanent rules that will reshape how you practice telemedicine psychiatry starting in 2027.

What the Ryan Haight Act Actually Says

Before COVID, the Ryan Haight Act effectively banned prescribing any controlled substance without at least one in-person medical evaluation. This federal law created a massive barrier to ADHD telehealth – you couldn’t start a patient on stimulants purely through virtual visits unless you fit into narrow exceptions (which, in practice, didn’t exist for most outpatient psychiatry).

The pandemic changed everything. In March 2020, the DEA waived the in-person requirement using public health emergency authority. That waiver has been extended repeatedly, most recently through the end of 2026. Translation: you can conduct an initial ADHD evaluation via live video, make a diagnosis, and prescribe stimulants without ever meeting the patient face-to-face.

Critical requirement: The telehealth encounter must use real-time, two-way audiovisual communication. Audio-only (phone calls) doesn’t cut it for prescribing Schedule II stimulants. Document that you used video, verify patient identity, and practice the same diagnostic rigor you would in-person.

What’s Coming in 2027: The DEA’s Permanent Telemedicine Rules

The DEA announced three new telemedicine rules in January 2025 that will govern controlled substance prescribing after the current extension expires. While final rule text isn’t published yet, here’s what the DEA has previewed:

Telemedicine Special Registration: Providers will be able to obtain a special DEA registration authorizing them to prescribe controlled substances via telehealth without in-person exams. This registration will come with mandatory safeguards:

• Nationwide PDMP (Prescription Drug Monitoring Program) checks for every controlled substance prescription
• Strict patient identity verification during audiovisual consultations
• Corporate-level registration requirements for telehealth platforms (like Klarity)

Established Patient Exception: If you’ve seen a patient in-person at least once (or another provider in your practice has), the new telemedicine restrictions won’t apply. You can continue telehealth follow-ups freely. It’s only treating brand-new patients you’ve never physically met that triggers the special rules.

30-Day Initial Supply Option: Early proposals suggested allowing a 30-day supply of Schedule II medications via telehealth without special registration, requiring an in-person visit or special registration for ongoing therapy. The DEA received over 38,000 public comments criticizing this as too restrictive, so expect modifications – but some version of time-limited initial prescribing may remain.

For ADHD providers, the takeaway is clear: obtain the telemedicine special registration when it becomes available. This will be your path to maintaining uninterrupted telehealth ADHD care in 2027 and beyond.

The Compliance Reality Nobody Talks About

Federal telehealth flexibilities don’t eliminate your other prescribing obligations. You still must:

• Hold a valid DEA registration covering the patient’s state
• Use electronic prescribing (EPCS) for controlled substances in most cases
• Check state PDMPs as required by state law (more on this below)
• Document a legitimate medical purpose and conduct a thorough evaluation
• Follow the same standard of care as in-person treatment

The DEA has been actively scrutinizing telehealth ADHD prescribing. Large telehealth companies faced investigations in 2022-2023 for alleged over-prescription of stimulants. The message: prescribe appropriately, document thoroughly, and don’t treat telehealth as a shortcut around proper evaluation.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Laws: Where It Gets Complicated

Federal law sets the floor, but states can add requirements. Here’s what matters in the six states with the highest demand for ADHD telehealth services.

California: Permissive and Getting More So

The good news: California explicitly allows telehealth examinations to satisfy prescribing requirements for controlled substances. No in-person visit required by state law – a video consultation meets the ‘appropriate prior examination’ standard under Business & Professions Code §2242.

PMHNP autonomy: California’s AB 890 created a pathway for nurse practitioners to achieve Full Practice Authority. By 2026, experienced NPs (those with 3+ years or 4,600+ hours under physician collaboration) can prescribe ADHD medications independently without a supervising physician. New grad NPs still need supervision initially, but this opens significant telehealth opportunities as more California PMHNPs gain independence.

Compliance requirements:

• Check the CURES PDMP database before initiating any Schedule II-IV prescription, and at least every 4 months for ongoing stimulant therapy (this is mandatory)
• Hold a California medical license – no shortcuts via compact or telehealth registration
• Use secure, HIPAA-compliant video platforms

The reality: California’s Medical Board hasn’t erected barriers to telehealth ADHD treatment. Follow standard-of-care evaluation practices, document your CURES checks, and you’re fine. The state’s progressive stance on NP independence will likely make California one of the easiest markets for telehealth ADHD care.

Texas: Physicians Only for Stimulants

The major restriction: Texas law prohibits nurse practitioners and physician assistants from prescribing Schedule II controlled substances in outpatient settings. Period. The only exceptions are highly specific – inpatient hospital orders, hospice patients, or emergency medication in hospital ERs.

For telehealth ADHD care in Texas, this means only physicians (MD/DO) can prescribe Adderall, Vyvanse, Ritalin, or other Schedule II stimulants. If you’re a PMHNP, you can evaluate the patient and manage non-medication aspects of ADHD care, but a physician must write the actual prescription.

Texas Board of Nursing guidance is unambiguous: ‘There are no other outpatient settings at which APRNs may prescribe Schedule II controlled substances.’ This isn’t changing anytime soon – recent legislative sessions reaffirmed telehealth access but did not expand APRN prescribing authority.

For psychiatrists: Texas is straightforward. Use the Interstate Medical Licensure Compact (IMLC) if you’re out-of-state and want to expedite a Texas license. Conduct video evaluations, document thoroughly, and prescribe via electronic prescription (Texas mandated EPCS for all controlled substances as of 2021).

PDMP quirk: Texas requires checking the PMP for opioids, benzodiazepines, barbiturates, and carisoprodol – but stimulants aren’t on the mandatory check list. Still, query it anyway as best practice before prescribing any ADHD medication.

The reality: If you’re building a telehealth ADHD practice serving Texas, budget for physician involvement. Platforms like Klarity handle this by ensuring Texas-licensed psychiatrists are available for medication management, with PMHNPs providing comprehensive evaluation and therapy.

Florida: Clear Exception for Psychiatric Treatment

The explicit carve-out: Florida Statutes §456.47 generally prohibits prescribing Schedule II controlled substances via telehealth – except for treatment of psychiatric disorders, inpatient care, hospice, or nursing facilities. ADHD qualifies as a psychiatric disorder, so Florida explicitly permits telehealth ADHD medication prescribing.

This legal clarity is actually refreshing. You’re not operating in a gray area; the state legislature specifically contemplated mental health telehealth when drafting this law in 2019.

Out-of-state provider option: Florida created a telehealth provider registration system allowing out-of-state clinicians to treat Florida patients without obtaining a full Florida license. Requirements include an active, unrestricted license in your home state, clean disciplinary record for 5+ years, and malpractice insurance. Once registered, you can prescribe ADHD medications to Florida patients under the psychiatric disorder exception.

PMHNP rules: Florida APRNs can prescribe controlled substances, but with nuances. General APRNs are limited to 7-day supplies of Schedule II medications. However, psychiatric nurses (PMHNPs with advanced psychiatric training and 2+ years post-graduate psychiatric clinical experience under a psychiatrist) are exempt from the 7-day restriction.

The catch: psychiatric NPs must practice under a written protocol agreement with a supervising psychiatrist. Florida law requires physician supervision for mental health APRNs – the state’s 2020 independence law covered only primary care, family medicine, and geriatrics, not psychiatry.

Compliance requirements:

• Register with Florida’s E-FORCSE PDMP and check it before prescribing controlled substances for patients 16+
• Document that your telehealth service falls under ‘psychiatric disorder treatment’ in your notes
• For out-of-state providers using the registration system, establish your Florida protocol relationship

The reality: Florida’s regulatory framework is provider-friendly for telehealth ADHD care. Just ensure your practice structure includes psychiatric physician oversight if using PMHNPs.

New York: Recently Updated and Aligned with Federal Law

May 2025 regulatory change: New York State Department of Health updated its controlled substance regulations to explicitly allow telehealth prescribing ‘consistent with federal law and other applicable state laws.’ This aligned New York with DEA’s telehealth flexibilities, removing any state-level conflict.

Before this update, New York’s 10 NYCRR §80.63 mirrored the Ryan Haight Act’s in-person requirement. Now, as long as the federal extension is in place (through 2026), you can prescribe ADHD medications via telehealth in New York without state interference.

PMHNP independence: New York is relatively progressive for nurse practitioners. After 3,600 hours of practice, NPs can practice independently without a written collaborative agreement (though they must maintain a defined collaborative relationship with a physician). PMHNPs in New York can prescribe Schedule II-V controlled substances with their own DEA registration and NYS Bureau of Narcotic Enforcement prescribing number.

No quantity limits: Unlike some states, New York doesn’t impose special Schedule II quantity limits for NPs. However, controlled substances are generally limited to 30-day supplies – except ADHD has a specific exception. New York allows up to 90-day supplies of stimulants for ADHD (or narcolepsy) if you use the appropriate prescription code (Code B for ADHD/minimal brain dysfunction). This applies to both physicians and NPs.

Mandatory compliance:

• Check the I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance (this is strictly enforced in New York)
• Use electronic prescribing – New York mandated EPCS for all controlled substances starting in 2016
• Obtain a NYS Bureau of Narcotic Enforcement prescribing number in addition to your DEA registration

The reality: New York’s 2025 regulatory update removed uncertainty. The state has high demand for ADHD services, welcomes tele-mental health, and offers good autonomy for experienced PMHNPs. Just stay on top of PMP checks – New York regulators are serious about prescription monitoring.

Pennsylvania: Follow Federal Rules, But Watch NP Limits

State approach: Pennsylvania has no specific state prohibition on telehealth controlled substance prescribing beyond federal requirements. The state’s Medical Board and Osteopathic Board confirmed that valid patient-provider relationships can be established via telemedicine, and prescribing is acceptable if it meets standard of care.

Pennsylvania has attempted comprehensive telehealth legislation multiple times, but much of current practice is governed by board policy rather than statute. The practical effect: if federal law allows it (as it currently does through 2026), Pennsylvania allows it.

PMHNP restrictions: Pennsylvania is a restricted-practice state for nurse practitioners. CRNPs must maintain a collaborative agreement with a physician. For prescribing Schedule II controlled substances, Pennsylvania regulations impose a 30-day supply limit for NPs, with any continuation beyond 30 days requiring physician approval.

This means a Pennsylvania PMHNP can prescribe an initial one-month supply of Adderall via telehealth, but before month two, the collaborating physician must review and approve ongoing therapy. The regulations also require monthly physician chart review of any NP’s Schedule II prescribing to ensure proper management.

For physicians: No special state limitations. Pennsylvania joined the Interstate Medical Licensure Compact in 2022, so out-of-state psychiatrists can expedite licensure if they want to treat Pennsylvania patients.

Compliance requirements:

• Check the Pennsylvania PDMP before the initial prescription of any controlled substance at the start of a new course of treatment (mandatory), and ideally for each refill
• Use electronic prescribing – Act 96 of 2018 mandated EPCS for controlled substances, effective October 2019
• Document collaborative agreements and physician oversight if using NPs

The reality: Pennsylvania welcomes telehealth for ADHD (especially in rural areas lacking psychiatrists), but NP practice requires structural physician involvement. For platforms managing this, it means ensuring a Pennsylvania-licensed psychiatrist reviews PMHNP cases at least monthly and approves ongoing stimulant therapy.

Illinois: Full Practice Authority Available for Experienced NPs

State telehealth stance: Illinois updated its Telehealth Act in 2021 to ensure parity and explicitly allow provider-patient relationships via telehealth. No state law prohibits controlled substance prescribing through telemedicine – Illinois defers to federal requirements.

Illinois Controlled Substance License: All providers who prescribe controlled substances in Illinois must obtain an Illinois CS license in addition to their DEA registration (administered through the Department of Financial & Professional Regulation). This is an extra administrative step but straightforward.

Two-tier APRN system: Illinois created a Full Practice Authority pathway for APRNs, which significantly impacts ADHD telehealth:

Tier 1 – Collaborative Practice: APRNs without FPA must work under a written collaborative agreement with a physician. Under collaboration, the APRN can prescribe Schedule II controlled substances for up to 30 days, with any continuation beyond 30 days requiring collaborating physician approval. The physician must also review the APRN’s Schedule II prescribing monthly.

Tier 2 – Full Practice Authority: APRNs who complete 4,000 hours of clinical practice under collaboration and 250 hours of continuing education/training can apply for FPA. With FPA, APRNs can prescribe independently, including Schedule II-V controlled substances, without physician collaboration.

Here’s the key detail for ADHD: Illinois law requires FPA APRNs to maintain a ‘consultation relationship’ with a physician only when prescribing Schedule II narcotic drugs (opioid analgesics) or benzodiazepines. Stimulants are Schedule II non-narcotics, so this consultation requirement doesn’t apply. An Illinois FPA PMHNP can prescribe Adderall independently via telehealth without any physician oversight.

PDMP: Illinois law mandates PMP checks for opioids and initial benzodiazepine prescriptions. It doesn’t explicitly require checks for stimulants, but best practice is to query the Illinois PMP (AWARxE) before prescribing ADHD medications.

The reality: Illinois offers an excellent environment for telehealth ADHD care, especially with FPA-credentialed PMHNPs. The state passed insurance parity laws and even requires Medicaid MCOs to offer 50% of mental health visits via telehealth. If you’re using NPs without FPA, structure physician oversight accordingly (monthly reviews, 30-day limits).

State-by-State Quick Reference: What You Actually Need to Know

The Economics of ADHD Telehealth: Why DIY Marketing Usually Fails

Let’s talk about what happens when you try to build your own telehealth ADHD practice through traditional marketing channels.

You’ll see advice online about ‘low-cost patient acquisition’ through Google Ads, SEO, or directory listings. The reality is drastically different once you factor in all the costs:

Google Ads reality: Mental health keywords cost $15-40+ per click. Most clicks don’t convert to booked appointments. Factor in ad spend testing, optimization time, landing page development, and no-shows from cold leads. Realistic cost per actually-seen ADHD patient through PPC: $200-400+.

SEO timeline: 6-12 months of consistent investment before generating meaningful patient flow. You’re competing with established practices, large telehealth companies with full SEO teams, and directories that dominate search results. Most solo providers don’t have the technical expertise or patience to see it through.

Psychology Today/Zocdoc: Monthly subscription fees ($29-50 on Psychology Today, higher on Zocdoc) plus per-booking charges ($35-100+ on Zocdoc depending on specialty and market). You’re also competing with hundreds of other providers on the same search results page. Total monthly cost when you include the subscription and per-booking fees: easily $500-1,500+ for a handful of patients.

Agency/consultant costs: If you hire help (which you’ll need to do this right), add $2,000-5,000+ per month for a marketing agency or SEO consultant. Plus staff time to handle inquiries, qualify leads, and schedule appointments.

The hidden costs: Failed campaigns that went nowhere, ad spend wasted during the learning curve, lost opportunity cost of your time managing marketing instead of seeing patients, no-show rates from unqualified leads who clicked an ad out of curiosity.

Add it all up: most providers spend $3,000-5,000+ per month on marketing with uncertain, inconsistent results. If you acquire 10-15 new patients in a good month, you’re paying $200-500 per patient – and that’s if you’re doing everything right.

The Platform Economics Alternative

Klarity Health uses a straightforward pay-per-appointment model. You pay a standard listing fee per new patient lead – and that’s it. No upfront marketing spend, no monthly subscriptions, no gambling on ad campaigns that might not work.

Here’s why this makes sense economically:

Pre-qualified patient matching: Klarity’s intake process matches patients to your specialty, availability, and accepted insurance before they ever reach you. You’re not paying for clicks from people who aren’t good fits.

No wasted spend: Traditional marketing means you pay whether the patient shows up or not. With Klarity, you only pay when qualified patients actually book appointments with you.

Built-in infrastructure: The platform fee covers the telehealth technology, EHR integration, credentialing support, billing assistance, and patient communication tools. Compare that to buying separate software subscriptions ($200-500/month for EHR + $50-150/month for telehealth platform + $100-300/month for scheduling/patient communication).

Both insurance and cash-pay flow: Klarity handles credentialing with major insurance panels and also attracts cash-pay patients. Building this mix independently takes months and often requires hiring a credentialing specialist.

You control your schedule: Set your availability, and Klarity fills those slots. You’re not committed to seeing X patients per month or maintaining a minimum monthly spend.

The business case: Instead of spending $3,000-5,000/month on marketing with uncertain ROI, you pay only when you see patients. That’s guaranteed return versus gambling on marketing channels where most solo providers fail.

FAQ: Your Top Questions About Telehealth ADHD Prescribing

Can I prescribe Adderall after just a video visit, or do I need to see the patient in-person first?

As of 2026, federal law allows you to prescribe Adderall and other Schedule II stimulants after a video-only evaluation, with no in-person visit required. This flexibility is in place through December 31, 2026 under DEA emergency extensions.

However, your evaluation must be thorough, use live two-way audiovisual communication (not just phone), and meet the same standard of care as an in-person visit. Document patient identity verification, conduct a complete ADHD assessment using DSM criteria, and review their medication history via your state PDMP.

After 2026, the DEA’s permanent rules will likely require providers to obtain a special telemedicine registration to continue prescribing without in-person exams.

What happens on January 1, 2027 when the current DEA extension expires?

The DEA is finalizing permanent telemedicine rules that will replace the temporary COVID-era waivers. Based on January 2025 announcements, providers will likely need to obtain a Telemedicine Special Registration to prescribe controlled substances to new patients without in-person exams.

This special registration will require mandatory nationwide PDMP checks, strict patient identity verification during video visits, and possibly periodic continuing education on telemedicine prescribing standards.

If you’ve already seen a patient in-person at least once (or another provider in your practice has), the new restrictions won’t apply – you can continue telehealth follow-ups normally.

The key action: watch for DEA rule publication in the Federal Register (expected mid-to-late 2026) and apply for the telemedicine special registration as soon as it becomes available. Platforms like Klarity will support providers through this transition and ensure you maintain uninterrupted patient access.

Do ADHD telehealth regulations differ for treating children vs. adults?

The core prescribing regulations (DEA rules, state telehealth laws) apply to both pediatric and adult ADHD patients. However, treating minors adds layers of complexity:

Consent requirements: You must obtain parent or legal guardian consent for treatment and medication. Most states require the parent/guardian to be present or available during the initial telehealth evaluation for minors.

Diagnostic evaluation: Pediatric ADHD diagnosis often requires collateral information from schools (teacher rating scales, report cards). While you can gather this via secure document upload, the evaluation must be comprehensive enough to justify stimulant medication in a child.

Dosing and monitoring: Pediatric patients typically start at lower doses with more frequent follow-ups. This is standard of care regardless of telehealth vs. in-person.

State-specific rules: Some states have special protocols for prescribing controlled substances to minors. For example, Florida requires psychiatric NPs to have a consulting pediatrician or psychiatrist when prescribing psychotropic controlled medications to patients under 18.

As an NP, how do I know if I can prescribe ADHD medications independently in my state?

Check three things:

1. Does your state allow NP prescribing of Schedule II controlled substances? (Most do, but Texas prohibits it entirely for outpatient NPs)

2. Does your state require physician collaboration, supervision, or a practice agreement? States fall into three categories:

• Full Practice Authority (FPA): NPs can prescribe independently after meeting experience requirements (e.g., California, Illinois with FPA credential, New York after 3,600 hours)
• Reduced Practice: NPs can prescribe but must have a collaborative agreement or physician supervision (e.g., Pennsylvania, Florida, Illinois without FPA)
• Restricted Practice: NPs cannot prescribe Schedule II at all or only in very limited settings (e.g., Texas)

1. Are there quantity limits or special approval requirements? Pennsylvania and Illinois (non-FPA) limit NP Schedule II prescriptions to 30 days with physician approval needed for continuation. Florida limits general APRNs to 7-day supplies (but psychiatric NPs are exempt).

Check your state Board of Nursing website and the Nurse Practice Act for current rules. If you’re planning to practice in multiple states via telehealth, you’ll need to understand the rules in each state where your patients are located.

Do I need to check the PDMP every time I prescribe ADHD medication?

It depends on state law, but best practice is yes.

States with mandatory PDMP checks for all Schedule II prescriptions: New York, California (initial + every 4 months), Florida (patients 16+), and Pennsylvania (initial prescription in a new course of treatment) explicitly require PDMP checks before prescribing stimulants.

States with mandatory checks for opioids/benzos but not stimulants: Texas, Illinois mandate PDMP checks for opioids and benzodiazepines but don’t explicitly require them for stimulants. However, most providers check anyway as standard practice.

Why you should check regardless: Reviewing the PDMP protects you and your patient. It reveals if the patient is receiving stimulants from multiple providers (possible diversion), has a history of early refills (potential misuse), or is on other controlled substances that might interact (benzodiazepines + stimulants can be concerning).

Document your PDMP review in every patient chart. If you discover concerning patterns, it doesn’t automatically disqualify the patient from treatment, but it should prompt a conversation and heightened monitoring.

Can I prescribe 90-day supplies of ADHD medications via telehealth, or am I limited to 30 days?

This varies significantly by state and provider type:

New York: Both physicians and experienced NPs can prescribe up to 90 days of stimulants for ADHD if you indicate the diagnosis with Code B on the prescription. This is a huge convenience factor for stable patients.

Pennsylvania NPs / Illinois NPs without FPA: Limited to 30-day supplies of Schedule II prescriptions, with physician approval required for any continuation beyond 30 days.

California, Florida (for psychiatric NPs), Illinois (FPA NPs): No state-specific quantity limits beyond what’s clinically appropriate. You could prescribe 90 days if the patient is stable and it meets standard of care.

Texas: Physicians have no quantity limits; NPs cannot prescribe Schedule II outpatient medications at all.

Federal DEA regulations allow up to a 90-day supply of Schedule II medications in some circumstances, but your state medical board rules and standard of care should guide your decision. Most telehealth providers start with 30-day prescriptions initially to establish stability before moving to longer supply periods.

What if my patient travels to another state – can I still prescribe their ADHD medication?

This is complicated. You must be licensed in the state where the patient is physically located at the time of treatment. If your patient temporarily travels to another state, you generally cannot prescribe or refill their ADHD medication unless you also hold a license in that state.

Exception: Some states have temporary visitor provisions or allowances for patients who are just passing through (usually for emergencies). But for routine refills, the safe answer is you need licensure in the patient’s location state.

Practical solution: Patients should plan ahead for travel. Write prescriptions before they leave to cover the time they’ll be away, or connect them with a local provider in their destination if they need care while traveling.

Interstate compacts: The Interstate Medical Licensure Compact (IMLC) streamlines the process for physicians to obtain licenses in multiple states. As of 2026, 40+ states participate. The APRN Compact exists but isn’t widely adopted yet. These compacts make multi-state practice more feasible but don’t eliminate the need for state-specific licensure.

How does Klarity handle state licensing and compliance for providers?

Klarity simplifies multi-state practice in several ways:

Credentialing support: We guide you through the licensing process for states where you want to practice and assist with insurance panel credentialing (typically a 90-120 day process that we manage).

PDMP compliance: Klarity’s EHR integration includes prompts for mandatory PDMP checks based on the patient’s state. We track state-specific requirements so you don’t have to memorize every nuance.

Automatic state law updates: When regulations change (like New York’s May 2025 update or upcoming DEA rules), we update provider protocols and notify you of new requirements.

Physician collaboration for states that require it: In states like Texas, Pennsylvania, and Florida where NPs need physician oversight for stimulant prescribing, Klarity provides access to collaborating psychiatrists within the platform structure.

Documentation templates: Our EHR includes state-specific templates that capture required elements (PDMP documentation, Code B for New York 90-day supplies, etc.).

The goal: you focus on clinical care; we handle regulatory complexity in the background.

Join a Platform That Actually Understands Psychiatric Telehealth

You became a provider to help patients with ADHD access life-changing treatment. You didn’t sign up to become an expert in DEA telemedicine regulations, multi-state licensing, PDMP compliance in six different systems, and the ever-shifting landscape of NP scope-of-practice laws.

Klarity Health was built specifically for psychiatric providers treating ADHD, depression, anxiety, and other conditions via telehealth. We handle patient acquisition, regulatory compliance, EHR/telehealth technology, billing, and credentialing so you can focus on clinical care.

Why providers choose Klarity:

• Pay only when you see patients: No upfront marketing costs, no monthly subscription fees, no wasted ad spend on unqualified leads
• Pre-qualified patients: Our intake process matches patients to your specialty and availability before they reach you
• Full compliance support: We track state-specific PDMP requirements, documentation rules, and prescribing regulations across all 50 states
• Both insurance and cash-pay: We credential you with major insurance panels and also provide cash-pay patient flow
• Built-in telehealth infrastructure: HIPAA-compliant video platform, integrated EHR with e-prescribing (including EPCS), scheduling, and patient communication
• You control your schedule: Set your availability and we fill those slots – no minimum commitments

Whether you’re a psychiatrist looking to expand your practice, an experienced PMHNP ready to leverage your Full Practice Authority, or a newer NP building your patient base with proper supervision, Klarity provides the infrastructure to practice telemedicine compliantly and profitably.

Explore how Klarity works → [Join Klarity’s Provider Network]

Sources and References

The regulatory information in this guide is based on current federal and state laws as of February 2026. Key sources include:

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026). Official government announcement of controlled substance prescribing flexibility extension through December 31, 2026. Available at: www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Healthcare Dive – ‘DEA, HHS extend telehealth controlled substance prescriptions flexibilities for fourth time’ by Emily Olsen (January 5, 2026). Industry analysis confirming Schedule II-V coverage. Available at: www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/

3. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules’ (January 16, 2025). Official summary of proposed permanent telemedicine regulations including special registration and PDMP requirements. Available at: www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

4. RxAgent Blog – ‘NP Prescriptive Authority by State: 2026 Comprehensive Guide’ (Updated December 28, 2025). Comprehensive state-by-state analysis of nurse practitioner prescribing authority with statute citations. Available at: rxagent.co/blog/np-prescribing-authority

5. Texas Board of Nursing – APRN Practice FAQ (Current as of 2025). Official state guidance confirming NP prohibition on outpatient Schedule II prescribing. Available at: www.bon.texas.gov/faqpracticeaprn.asp.html

6. Florida Statutes – Section 456.47 (Telehealth law with psychiatric disorder exception) and Section 464.012 (APRN prescribing rules). Current through 2025 legislative session. Available at: www.leg.state.fl.us/statutes/

7. New York State Department of Health – Bureau of Narcotic Enforcement Guidance on Prescribing Controlled Substances via Telehealth (Effective May 21, 2025). Official state regulatory update aligning NY law with federal telehealth allowances. Summary available at: www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care